WO2000074686A1 - Modulators of methylation for control of bacterial virulence - Google Patents
Modulators of methylation for control of bacterial virulence Download PDFInfo
- Publication number
- WO2000074686A1 WO2000074686A1 PCT/US2000/015865 US0015865W WO0074686A1 WO 2000074686 A1 WO2000074686 A1 WO 2000074686A1 US 0015865 W US0015865 W US 0015865W WO 0074686 A1 WO0074686 A1 WO 0074686A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sahh
- methylation
- virulence
- bacterial
- compound
- Prior art date
Links
- 230000001018 virulence Effects 0.000 title claims abstract description 15
- 230000001580 bacterial effect Effects 0.000 title claims abstract description 12
- 238000007069 methylation reaction Methods 0.000 title description 28
- 230000011987 methylation Effects 0.000 title description 25
- 238000000034 method Methods 0.000 claims abstract description 26
- 150000001875 compounds Chemical class 0.000 claims abstract description 18
- 208000035143 Bacterial infection Diseases 0.000 claims abstract description 13
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 13
- 102000007357 Methionine adenosyltransferase Human genes 0.000 claims abstract description 8
- 108010007784 Methionine adenosyltransferase Proteins 0.000 claims abstract description 8
- 102000004190 Enzymes Human genes 0.000 claims description 27
- 108090000790 Enzymes Proteins 0.000 claims description 27
- ZJUKTBDSGOFHSH-WFMPWKQPSA-N S-Adenosylhomocysteine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCC[C@H](N)C(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZJUKTBDSGOFHSH-WFMPWKQPSA-N 0.000 claims description 14
- 108010043135 L-methionine gamma-lyase Proteins 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 8
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 7
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical class OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 6
- 150000003838 adenosines Chemical class 0.000 claims description 5
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 4
- 229960005305 adenosine Drugs 0.000 claims description 4
- -1 adenosine arabinoside Chemical class 0.000 claims description 3
- 102000008109 Mixed Function Oxygenases Human genes 0.000 claims description 2
- 108010074633 Mixed Function Oxygenases Proteins 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 abstract description 25
- 102000005234 Adenosylhomocysteinase Human genes 0.000 abstract description 21
- 108020002202 Adenosylhomocysteinase Proteins 0.000 abstract description 21
- 239000000203 mixture Substances 0.000 abstract description 14
- 238000006243 chemical reaction Methods 0.000 abstract description 6
- 239000004480 active ingredient Substances 0.000 abstract description 5
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 3
- 102000016397 Methyltransferase Human genes 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 229960004452 methionine Drugs 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- OLXZPDWKRNYJJZ-UHFFFAOYSA-N 5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol Chemical compound C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(CO)O1 OLXZPDWKRNYJJZ-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 101710159129 DNA adenine methylase Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000000779 depleting effect Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- DBZQFUNLCALWDY-PNHWDRBUSA-N (2r,3r,4s,5r)-2-(4-aminoimidazo[4,5-c]pyridin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=CC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O DBZQFUNLCALWDY-PNHWDRBUSA-N 0.000 description 1
- FLDHIRRXGKLJDM-BNWFAOCJSA-N (2s)-2-amino-4-[(e)-1,2-dichloroethenyl]sulfanylbutanoic acid Chemical compound OC(=O)[C@@H](N)CCS\C(Cl)=C/Cl FLDHIRRXGKLJDM-BNWFAOCJSA-N 0.000 description 1
- MZBVTOOFTWJQRK-DNJJZFMCSA-N (2s)-2-amino-4-[[(1s,3s,4r)-4-(6-aminopurin-9-yl)-2,3-dihydroxycyclopentyl]methylsulfanyl]butanoic acid Chemical compound O[C@@H]1C(O)[C@@H](CSCC[C@H](N)C(O)=O)C[C@H]1N1C2=NC=NC(N)=C2N=C1 MZBVTOOFTWJQRK-DNJJZFMCSA-N 0.000 description 1
- ILMNSCQOSGKTNZ-UHFFFAOYSA-N 2-[1-(6-aminopurin-9-yl)-2-oxoethoxy]-3-hydroxypropanal Chemical compound NC1=NC=NC2=C1N=CN2C(OC(CO)C=O)C=O ILMNSCQOSGKTNZ-UHFFFAOYSA-N 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical class NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- MKAZZYJKLNQWGP-UHFFFAOYSA-N [N]CCCCCCN Chemical class [N]CCCCCCN MKAZZYJKLNQWGP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 108010079916 homocysteinase Proteins 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the invention relates to the control of bacterial infection in animals. More particularly, it relates to the use of inhibitors of bacterial transmethylation pathways to control such infection.
- SAHH S-adenosyl-homocysteine hydrolase
- SAH S-adenosyl-homocysteine
- SAHH catalyzes the equilibrium between SAH and its lysis products, adenosine and homocysteine. It is significant in regulating the levels of adenosine as well.
- SAHH has been used as a target for antiparasitic and antiviral chemotherapy as described by Minatto, et al,. Experimental Parasitol (1998) 175-180.
- SAM is the source of methyl groups for all transmethylation reactions and SAH constitutes a methylation inhibitor.
- methylation status and control of transmethylation is significant in the metabolism and life cycle of bacterial cells, and although means to modulate methylation status and transmethylation are known in the art, surprisingly, such means have not been used to control or otherwise ameliorate bacterial infection.
- the present invention is directed to taking advantage of the significance of methylation in designing antibiotic protocols.
- the invention provides methods and compositions for the amelioration of bacterial virulence by modulating the transesterification systems of the bacteria through control of cellular components that catalyze the relevant reactions or by depleting the reservoir of available methyl groups.
- the invention provides means to assess the potency of antivirulent compound candidates by assaying their effects on these cellular components.
- the invention is directed to a method to diminish bacterial virulence by supplying agents which inhibit enzymes that affect methylation such as transmethylases, S-adenosyl methionine synthetase (SAMS), S-adenosyl-homocysteine hydroxylase (SAHH), or DNA adenine methylase (Dam).
- agents which inhibit enzymes that affect methylation such as transmethylases, S-adenosyl methionine synthetase (SAMS), S-adenosyl-homocysteine hydroxylase (SAHH), or DNA adenine methylase (Dam).
- SAMS S-adenosyl methionine synthetase
- SAHH S-adenosyl-homocysteine hydroxylase
- Dam DNA adenine methylase
- the invention is directed to methods to identify successful antivirulent agents by assessing their ability to inhibit enzymes involved in methylation, such as transmethylases, SAHH or Dam.
- the invention is directed to a method of treating virulent bacterial infection by administering a composition comprising methioninase, or an expression system therefor.
- the present invention is based on the recognition that transmethylation reactions and methylation levels are significant in controlling bacterial infectivity, proliferation and growth. Although this recognition exists in the art, no advantage has been taken of this recognition to provide antibiotic protocols for prophylactic or therapeutic treatment of bacterial infection.
- the present invention remedies this by providing not only therapeutic protocols and compositions useful in combating bacterial infection, but also in providing means to identify new agents as antibiotics by virtue of their ability to interfere with methylation traffic in bacteria.
- the invention's contribution is particularly important in view of the ability of bacteria to acquire resistance to antibiotics as these compounds become more universally employed. By basing antibiotic treatment on metabolic functions which have not so far been targeted, the possibility of acquisition of resistance as a simple modification of resistance pathways already acquired is minimized.
- any agent which interferes with the methylation pathways critical to virulence, infectivity, or growth and proliferation may be targeted.
- Some appropriate targets include the enzymes which catalyze the transmethylation reactions er se, such as Dam, enzymes which regulate the levels of methyl donors, such as SAHH. and enzymes which directly regulate the supply of methyl groups such as methioninase.
- RNA methyltransferase enzymes As is recognized in the '104 patent, a multiplicity of agents that inhibit RNA methyltransferase enzymes is exemplified by SAH itself and its analogs, homocysteine, adenine derivatives, and SAM analogs and derivatives such as 6-amino-l- hexylnitrogen analogs of SAM. Other inhibitors of RNA methyltransferases are also disclosed. Agents that inhibit SAHH are also recognized, such as adenosine dialdehyde and 3-deaza adenosine, as well as structural analogs of SAH.
- the invention comprises compositions and methods for diminishing the virulence of bacterial infection which use as an active ingredient at least one inhibitor of SAHH.
- SAH is a methylation inhibitor.
- a wide variety of such inhibitors is known.
- suicide inactivation of human lymphoblast SAHH by 2'-deoxyadenosine and adenine arabinoside has been reported by Hershfield, M.S., JBiol Chem (1979) 254:22-25.
- the ability of 6'-(E and Z)-halohomovinyl derivatives of adenosine to inhibit SAHH was reported by Wnuk, S., et al, J Med Chem (1994) 37:3579-3587.
- S-(l,2-dichlorovinyl)-L-homocysteine DCVHC
- Lash, L.H., et al, Arch Biochem Biophys (1986) 251 :432-439 ACCVHC
- S AM-dependent methyltransferases in general which are analogs of S-aristeromycinyl-L-homocysteine are disclosed by Houston, D.M., et al, J Med Chem (1985) 28:478-482. All of these documents are incorporated herein by reference.
- Suitable inhibitors for these enzymes are also known in the art.
- the levels of activity of the methioninase are enhanced.
- Use of methioninase in treating cancer and other hyperproliferative conditions is disclosed in PCT publications W094/11535 and W096/40284.
- Treatment of tumors by gene therapy involving the expression of the methioninase coding sequence is described in U.S. serial number 09/195,055 filed 18 November 1998 and incorporated herein by reference.
- the invention thus also relates to depleting the source of methyl groups by supplying methioninase to deplete the levels of methionine.
- the use of methioninase to effect such depletion in order to treat malignant diseases has been disclosed in U.S. Patent No. 5,690,929 incorporated herein by reference.
- the methods of administration and formulation therein described are equally applicable here.
- compositions of the invention may comprise as active ingredients one or more specific inhibitors of SAHH or inhibitors of SAM-dependent transmethylases in general. Many of these inhibitors are adenosine analogs as is understood in the above-cited art; however other suitable inhibitors are numerous and known in the art.
- the antivirulence compounds regulating methylation levels and status can be administered to suitable subjects either as the sole active ingredient, or several such compounds may be used in combination, or these may be used in combination with additional antimicrobial agents. However, unlike the case with the description of U.S. patent 5,872,104, co- administration with traditional antibiotics is not required.
- the nature of the formulation and mode of administration will depend on the nature of the subject, the nature of the bacterial infection, the severity of the infection, and a variety of other factors well known to medical and veterinary practitioners. Suitable subjects include, in addition to humans, domestic animals and avians, livestock intended for commercial purposes, experimental animals for use in research, and the like. Depending on the parameters cited above, the mode of administration may be systemic or topical or local. Systemic administration may be by injection or by transdermal, transmucosal, or oral administration. Suitable formulations for any appropriate mode of administration may be found, for example, in Remington's Pharmaceutical Sciences, latest edition, Mack Publishing Co., Easton, PA.
- the methylation modulating virulence inhibitors within the scope of the invention are typically small molecules that are readily subject to conventional formulation and administration techniques.
- the compounds used for the antibiotics may be administered orally in the form of capsules, pills, or powders or may be contained in syrup. They may also be administered intranasally using formulations which include surfactants in order to penetrate nasal barriers; by suppository, by transdermal patch, by injection, either intravenously or by subcutaneous or intramuscular or intraperitoneal injection.
- Compositions suitable for intravenous injection typically may include, in addition to isotonic carrier media, liposomal formulations of the active ingredient.
- the agents may be administered in the form of eye drops; for infections localized at wound sites, local administration topically is also preferred.
- administration of compounds other than small molecules, such as methioninase more specialized techniques are required as proteins are difficult to administer systemically.
- proteins can be injected, typically intravenously and by proper formulation other routes of administration may be also used. Intranasal administration has been frequently successful.
- a variety of means for administration is available in the art generally.
- the protein may be supplied by providing a suitable expression system either using simply naked DNA or including in the DNA administered a means to effect integration of the DNA into the genetic material of a cell which may be modified ex vivo and readministered.
- viral vectors such as adenovirus, retrovirus and the like may be directly employed.
- the techniques for such "genetic therapy" are currently under development and the techniques themselves do not constitute part of the invention. That is to say that the insight provided by the inventors herein is that enhanced levels of methioninase are helpful in combating bacterial infection, however these enhanced levels are achieved.
- the invention provides means to identify compounds useful in ameliorating bacterial infection virulence. Isolated forms of transmethylation enzymes, such as DNA adenosine methylase (Dam) or of enzymes that modulate methylation in general, such as SAHH, may be used.
- Dam DNA adenosine methylase
- SAHH enzymes that modulate methylation in general
- isolated form is meant that the enzyme is present in the assay in a context in which it is not natively found.
- the isolated enzymes may also, preferably, be purified for ease of interpretation of the assay results.
- Means to assay the activity of these enzymes are conventional and involve supplying substrates which cause detectable label either to increase or decrease as they are converted to product by the relevant enzyme. In general, compounds which inhibit these enzymes will be useful to ameliorate bacterial virulence.
- a wide variety of assay techniques to determine the ability of a compound being tested to inhibit a particular enzyme is available in the art.
- potential inhibitors of SAHH may be added as test compounds to reaction mixtures which contain the isolated enzyme, SAH (the substrate) and a homocysteinase.
- SAH the substrate
- homocysteinase the homocysteine produced by the action of SAH hydrolase on SAH can then be detected by measuring, for example, the hydrogen sulfide, ammonia, or x-ketoglutarate produced by the lysis of homocysteine.
- Such assay techniques are described, for example, in U.S. patent 6,066,467 and PCT application US98/15430, both incorporated herein by reference.
- a wide variety of assay systems which employ SAHH, Dam and other enzymes which modulate methylation is available in the art.
- the purified form of the relevant enzymes can be obtained by extraction from their natural source, recombinant synthesis, or, in some cases, by chemical synthesis from the individual amino acid constituents.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Investigating Or Analyzing Materials By The Use Of Fluid Adsorption Or Reactions (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Cookers (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00939727A EP1183034B1 (en) | 1999-06-09 | 2000-06-09 | Modulators of methylation for control of bacterial virulence |
AU54769/00A AU784794B2 (en) | 1999-06-09 | 2000-06-09 | Modulators of methylation for control of bacterial virulence |
AT00939727T ATE310524T1 (en) | 1999-06-09 | 2000-06-09 | MODULATORS OF METHYLATION FOR CONTROLLING BACTERIAL VIRULENCE |
JP2001501222A JP2003501391A (en) | 1999-06-09 | 2000-06-09 | Methylation modulators for controlling bacterial virulence |
DE60024257T DE60024257T2 (en) | 1999-06-09 | 2000-06-09 | MODULATORS OF METHYLATION FOR THE CONTROL OF BACTERIAL VIRULENCE |
CA002375383A CA2375383C (en) | 1999-06-09 | 2000-06-09 | Modulators of methylation for control of bacterial virulence |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13830799P | 1999-06-09 | 1999-06-09 | |
US60/138,307 | 1999-06-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000074686A1 true WO2000074686A1 (en) | 2000-12-14 |
Family
ID=22481445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/015865 WO2000074686A1 (en) | 1999-06-09 | 2000-06-09 | Modulators of methylation for control of bacterial virulence |
Country Status (8)
Country | Link |
---|---|
US (1) | US6632430B2 (en) |
EP (1) | EP1183034B1 (en) |
JP (1) | JP2003501391A (en) |
AT (1) | ATE310524T1 (en) |
AU (1) | AU784794B2 (en) |
CA (1) | CA2375383C (en) |
DE (1) | DE60024257T2 (en) |
WO (1) | WO2000074686A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1644020A2 (en) * | 2003-06-23 | 2006-04-12 | Anticancer, Inc. | Lyase treatment for p. carinii |
US9365625B1 (en) | 2011-03-31 | 2016-06-14 | David Gordon Bermudes | Bacterial methionine analogue and methionine synthesis inhibitor anticancer, antiinfective and coronary heart disease protective microcins and methods of treatment therewith |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7026155B2 (en) * | 1999-02-02 | 2006-04-11 | Regents Of The University Of California | Method of reducing bacterial proliferation |
KR20110097841A (en) * | 2001-12-31 | 2011-08-31 | 안티캔서, 인코포레이티드 | System for monitoring bacterial tumor treatment |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0334361A2 (en) * | 1988-03-25 | 1989-09-27 | Merrell Dow Pharmaceuticals Inc. | Novel acetylenic, cyano and allenic aristeromycin/adenosine derivatives |
EP0347852A2 (en) * | 1988-06-20 | 1989-12-27 | Merrell Dow Pharmaceuticals Inc. | Novel neplanocin derivatives |
EP0365849A2 (en) * | 1988-09-27 | 1990-05-02 | Merrell Dow Pharmaceuticals Inc. | Novel 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl adenosine derivatives |
WO1996020010A1 (en) * | 1994-12-27 | 1996-07-04 | Oridigm Corporation | Combination for reducing antimicrobial resistance using a methylation inhibitor in combination with an antibiotic |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5455727A (en) | 1977-10-07 | 1979-05-04 | Sankyo Co Ltd | Method for preventing growth of mold |
US4381004A (en) | 1981-01-15 | 1983-04-26 | Biomedics, Inc. | Extracorporeal system for treatment of infectious and parasitic diseases |
US4507287A (en) | 1983-06-20 | 1985-03-26 | Dixon Glen J | Preparation and method for the treatment of acne |
US6001840A (en) | 1990-03-06 | 1999-12-14 | Southern Research Institute | Methods of treatment of viral infections using carbocyclic deoxyguanosine analogs |
-
2000
- 2000-06-09 CA CA002375383A patent/CA2375383C/en not_active Expired - Fee Related
- 2000-06-09 WO PCT/US2000/015865 patent/WO2000074686A1/en active IP Right Grant
- 2000-06-09 DE DE60024257T patent/DE60024257T2/en not_active Expired - Lifetime
- 2000-06-09 JP JP2001501222A patent/JP2003501391A/en active Pending
- 2000-06-09 EP EP00939727A patent/EP1183034B1/en not_active Expired - Lifetime
- 2000-06-09 AT AT00939727T patent/ATE310524T1/en not_active IP Right Cessation
- 2000-06-09 AU AU54769/00A patent/AU784794B2/en not_active Ceased
-
2002
- 2002-12-30 US US10/334,532 patent/US6632430B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0334361A2 (en) * | 1988-03-25 | 1989-09-27 | Merrell Dow Pharmaceuticals Inc. | Novel acetylenic, cyano and allenic aristeromycin/adenosine derivatives |
EP0347852A2 (en) * | 1988-06-20 | 1989-12-27 | Merrell Dow Pharmaceuticals Inc. | Novel neplanocin derivatives |
EP0365849A2 (en) * | 1988-09-27 | 1990-05-02 | Merrell Dow Pharmaceuticals Inc. | Novel 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl adenosine derivatives |
WO1996020010A1 (en) * | 1994-12-27 | 1996-07-04 | Oridigm Corporation | Combination for reducing antimicrobial resistance using a methylation inhibitor in combination with an antibiotic |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1644020A2 (en) * | 2003-06-23 | 2006-04-12 | Anticancer, Inc. | Lyase treatment for p. carinii |
EP1644020A4 (en) * | 2003-06-23 | 2009-04-08 | Anticancer Inc | Lyase treatment for p. carinii |
US9365625B1 (en) | 2011-03-31 | 2016-06-14 | David Gordon Bermudes | Bacterial methionine analogue and methionine synthesis inhibitor anticancer, antiinfective and coronary heart disease protective microcins and methods of treatment therewith |
Also Published As
Publication number | Publication date |
---|---|
CA2375383C (en) | 2008-07-29 |
EP1183034B1 (en) | 2005-11-23 |
EP1183034A1 (en) | 2002-03-06 |
DE60024257T2 (en) | 2006-07-20 |
CA2375383A1 (en) | 2000-12-14 |
AU5476900A (en) | 2000-12-28 |
AU784794B2 (en) | 2006-06-22 |
US6632430B2 (en) | 2003-10-14 |
JP2003501391A (en) | 2003-01-14 |
DE60024257D1 (en) | 2005-12-29 |
US20030138414A1 (en) | 2003-07-24 |
ATE310524T1 (en) | 2005-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chen et al. | Mechanism of action of the novel anticancer agent 6-fluoro-2-(2′-fluoro-1, 1′-biphenyl-4-yl)-3-methyl-4-quinolinecarboxylic acid sodium salt (NSC 368390): inhibition of de novo pyrimidine nucleotide biosynthesis | |
Kokkinakis et al. | Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice | |
Birnie et al. | Studies of fluorinated pyrimidines. XVIII. The degradation of 5-fluoro-2'-deoxyuridine and related compounds by nucleoside phosphorylase | |
Emura et al. | An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA | |
Wilkinson et al. | The mechanism of 5-fluorouridine toxicity in Novikoff hepatoma cells | |
WO1996020010A1 (en) | Combination for reducing antimicrobial resistance using a methylation inhibitor in combination with an antibiotic | |
Webley et al. | Deoxyuridine triphosphatase (dUTPase) expression and sensitivity to the thymidylate synthase (TS) inhibitor ZD9331 | |
Bruchelt et al. | Ascorbic acid enhances the effects of 6-hydroxydopamine and H2O2 on iron-dependent DNA strand breaks and related processes in the neuroblastoma cell line SK-N-SH | |
AU2016367112B2 (en) | Combination for the effective treatment of metastatic cancer in patients | |
Weber et al. | Multi-enzyme-targeted chemotherapy by acivicin and actinomycin | |
Olah et al. | Phase and cell cycle specificity of pyrazofurin action | |
CA2375383C (en) | Modulators of methylation for control of bacterial virulence | |
Della Ragione et al. | Effect of analogues of 5′-methylthioadenosine on cellular metabolism. Inactivation of S-adenosylhomocysteine hydrolase by 5′-isobutylthioadenosine | |
Balestri et al. | Key role of uridine kinase and uridine phosphorylase in the homeostatic regulation of purine and pyrimidine salvage in brain | |
Weber et al. | Molecular targets of anti-glutamine therapy with acivicin in cancer cells | |
Kensler et al. | Therapeutic effects of acivicin and N-(phosphonacetyl)-L-aspartic acid in a biochemically designed trial against a N-(phosphonacetyl)-L-aspartic acid-resistant variant of the Lewis lung carcinoma | |
Loh et al. | Synergistic effects with inhibitors of de novo pyrimidine synthesis, acivicin, and N-(phosphonacetyl)-L-aspartic acid | |
US20070275988A1 (en) | Transition state structure and inhibitors of thymidine phosphorylases | |
US6017962A (en) | Method of depletion of methionine in plasma and solid tumors and uses thereof | |
Pereira-Maróstica et al. | Harmful effects of chlorhexidine on hepatic metabolism | |
Perrin | CHEMOPROPHYLAXIS AND VIRUSES OF THE RESPIRATORY TRACT: SOME NEW APPROACHES TO ANTIVIRAL CHEMOTHERAPY, METALLOENZYME INHIBITION, AND TRANSPORT BY LIPOSOMES | |
Achleitner et al. | Inactivation by acivicin of rat brain CTP and GMP synthetases and depression of CTP and GTP concentrations | |
Saydjari et al. | The Effects of 2-Deoxy-D-Glucoseand α-Difluoromethylornithine on the Growth of Pancreatic Cancer in Vivo | |
Berne et al. | Concurrent allopurinol and 5-fluorouracil: 5-fluoro-2′-deoxyuridylate formation and thymidylate synthase inhibition in rat colon carcinoma and in regenerating rat liver | |
Chu et al. | Enhancement of 5-fluoro-2′-deoxyuridine antineoplastic activity by 5-benzyloxybenzyloxybenzylacyclouridine in a human colon carcinoma cell line |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AG AU CA DZ JP MZ |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2375383 Country of ref document: CA Ref country code: CA Ref document number: 2375383 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 501222 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000939727 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 54769/00 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2000939727 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000939727 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 54769/00 Country of ref document: AU |